Impact of COVID-19-related regulatory changes on nationwide access to buprenorphine: An interrupted time series design

BACKGROUND: The impact of COVID-19-related healthcare changes on access to buprenorphine (BUP) nationwide in the US is unknown. METHODS: We conducted an interrupted time series with the IQVIA LRx database. The study timeline included BUP prescriptions from 52 weeks before (2/23/19–2/21/20) to 52 wee...

Descripción completa

Detalles Bibliográficos
Autores principales: Roy, Payel Jhoom, Callaway Kim, Katherine, Suda, Katie, Luo, Jing, Wang, Xiaoming, Olejniczak, Donna, Liebschutz, Jane M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Full Length Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9851915/
https://www.ncbi.nlm.nih.gov/pubmed/36694665
http://dx.doi.org/10.1016/j.dadr.2023.100135

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9851915/
https://www.ncbi.nlm.nih.gov/pubmed/36694665
http://dx.doi.org/10.1016/j.dadr.2023.100135

Ejemplares similares